How HAART Works: Targeting HIV Replication at Multiple Steps

Highly Active Antiretroviral Therapy (HAART) combines ≥3 antiretrovirals from ≥2 classes to maximally suppress HIV replication. Each class targets a distinct viral lifecycle step:

  1. Entry Inhibitors (maraviroc, enfuvirtide): Block CCR5 co-receptor or gp41 fusion.
  2. NRTIs (tenofovir, emtricitabine, abacavir): Chain-terminate reverse transcription.
  3. NNRTIs (efavirenz, dolutegravir, rilpivirine): Allosterically inhibit reverse transcriptase.
  4. Integrase Inhibitors (bictegravir, dolutegravir, raltegravir): Block viral DNA integration into host genome.
  5. Protease Inhibitors (darunavir, atazanavir, lopinavir): Prevent Gag-Pol polyprotein cleavage → immature, non-infectious virions.

Clinical Impact

  • Sustained viral suppression (<50 copies/mL) → immune recovery (CD4↑)
  • Prevents AIDS-defining illnesses, reduces transmission (U=U)
  • Requires lifelong adherence; resistance emerges with interruptions
  • Monitoring: viral load q3–6mo, resistance testing at failure

HAART transforms HIV into a manageable chronic condition but is not curative.

HIV & AIDS - Related Articles